A Multiple Dose Study to Evaluate Subcutaneous AMG 108 in Subjects With Rheumatoid Arthritis
Rheumatoid Arthritis
About this trial
This is an interventional treatment trial for Rheumatoid Arthritis focused on measuring ACR criteria, methotrexate, DMARDs, patient reported outcomes, joint assessment
Eligibility Criteria
Inclusion Criteria: Subjects with active rheumatoid arthritis as diagnosed by meeting ACR classification criteria for at least 6 months. Must be taking MTX consecutively for >/= 12 weeks and at a stable dose of methotrexate at 15-25 mg weekly for at least 4 weeks prior to screening Exclusion Criteria: Receipt of commercial or experimental biologic therapies for the treatment of inflammatory disease Presence of serious infection Class IV rheumatoid arthritis Prior or current history of tuberculosis infection or exposure Any other DMARDs other than methotrexate within 6 weeks of screening Pregnant or nursing Receipt of live vaccines within 3 months Felty's syndrome
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Placebo Comparator
1
3
2
4
196 subjects
196 subjects
196 subjects
196 subjects